Assessing Legend Biotech (LEGN) Valuation After Recent Share Price Rebound From Longer Term Weakness

Legend Biotech stock reaction and recent performance context

Legend Biotech (NasdaqGS:LEGN) has been drawing attention after recent price moves, with the stock up around 9% over the past week and roughly 7% over the past month, while showing weaker year to date and 1 year returns.

Those mixed returns, including a 42% 1 year total return decline and a 63% 3 year total return decline, have investors reassessing how the current US$19.14 share price compares with the company’s latest fundamentals.

See our latest analysis for Legend Biotech.

The recent 7 day share price return of 9.43% and 30 day share price return of 7.17% contrast with weaker 90 day and year to date share price returns of 11.02% declines. Meanwhile, 1 year and 3 year total shareholder returns of 41.79% and 62.67% declines point to momentum rebuilding from a lower base as investors reassess risk and potential around the current US$19.14 share price.

If you are weighing up where to look next in the sector, this could be a good moment to broaden your watchlist with 37 healthcare AI stocks

With Legend Biotech trading at US$19.14 alongside an analyst target of US$57.22 and an intrinsic value estimate suggesting a discount, investors may need to consider whether there is a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 67.4% Undervalued

Legend Biotech's most followed narrative pins fair value at about $58.70 per share against the recent $19.14 close, setting up a wide valuation gap that hinges on how its cell therapy platform scales in the years ahead.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.

Read the complete narrative.

Curious what kind of revenue curve that wider patient pool implies, and how much margin uplift is baked into that 7% plus discount rate view? The narrative leans heavily on a profit swing from losses to meaningful earnings and a future earnings multiple that sits well above the broader US biotechs group, all wrapped into a fair value almost triple the current share price. The full story is in how those growth, margin and valuation pieces fit together.

Result: Fair Value of $58.70 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that story can quickly change if CARVYKTI faces safety or competitive setbacks, or if high R&D spending keeps Legend Biotech further from profitability.

Find out about the key risks to this Legend Biotech narrative.

Next Steps

If this mix of caution and optimism feels relevant to your own thinking, now is a good time to check the details yourself and stress test the upside case. To see exactly what the market is rewarding, take a closer look at the 2 key rewards

Looking for more investment ideas?

If Legend Biotech is on your radar, do not stop there, use the Simply Wall St Screener to spot other opportunities that could sharpen your portfolio.

• Target steady compounding by focusing on companies with reliable payouts and resilience through the 12 dividend fortresses.
• Hunt for quality at a discount by zeroing in on companies that screen as 62 high quality undervalued stocks.
• Prioritise peace of mind by focusing on businesses that pass the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com